{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"262"}],"units":"Participants"}],"description":"Criteria for ECG abnormalities included heart rate: increase of \\>15 bpm from baseline value and \\>=120 bpm, decrease of \\>15 bpm from baseline value and \\<=45 bpm; PR interval: change of \\>=20 msec from baseline value and \\>=220 milliseconds (msec); QRS interval \\>=120 msec; QTcB interval \\>500 msec, increase of \\>60 msec from baseline; \\>450 msec (Men) or \\>470 msec (Women). QT interval using Fridericia's correction (QTcF) \\>500 msec, increase of \\>60 msec from baseline, \\>450 msec (Men) or \\>470 msec (Women). The number of participants with ECG abnormalities during On-treatment period are reported. On-Treatment was defined as values collected after the date of the first dose of test article up until the last date of test article +28 days.","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"},{"description":"Participants with Philadelphia chromosome-positive CML received imatinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG001","title":"Imatinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all participants who received at least 1 dose of study medication with treatment assignments designated to actual study treatment received. Here, \"N\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (up to Month 60)","title":"Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}